Last --
Change Today 0.00 / 0.00%
Volume 0.0
ZLIXY On Other Exchanges
Symbol
Exchange
Continuous
OTC US
Frankfurt
OTC US
All times are local (Market data is delayed by at least 15 minutes).

zeltia sa-unspon adr (ZLIXY) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZELTIA SA-UNSPON ADR (ZLIXY)

Related News

No related news articles were found.

zeltia sa-unspon adr (ZLIXY) Related Businessweek News

No Related Businessweek News Found

zeltia sa-unspon adr (ZLIXY) Details

Zeltia, S.A. operates in the biopharmaceutical industry and consumer chemical sectors. It researches, develops, produces, and markets various types of bioactive products of marine origin for application in oncology; and products with therapeutic activity based on reducing or silencing gene expression and pharmaceutical derivatives of same in a range of formulations, as well as develops and markets biopharmaceutical applications, diagnosis, and related services. The company’s products include Yondeli, a marketed product for the treatment of ovarian cancer and soft tissue sarcoma; Aplidi, which is in Phase III trials for the treatment of multiple myeloma, as well as in angioimmunoblastic Tcell lymphoma; Zalypsi that is in Phase II trials for the treatment of multiple myeloma; PM1183, which has completed Phase IIb trials for the treatment of platinum-refractory/resistant ovarian cancer; PM060184 that is in Phase I trials for the treatment of various types of tumors; and SYL040012, which is in Phase IIB clinical trials for the treatment of glaucoma. It also develops and markets diagnosis kits. In addition, the company is involved in the manufacture and sale of wood and metal protective and decorative products, paints, and other related products; manufacture and marketing of domestic and industrial insecticides and air fresheners for household use; manufacture and sale of automatic aerosol dispensers under the Copyrmatic brand; and production of products for ecological farming. Further, it provides services for treating and protecting wood, and repairing and preserving structures, as well as insect control and disinfection services. Zeltia, S.A. was founded in 1939 and is headquartered in Madrid, Spain.

Founded in 1939

zeltia sa-unspon adr (ZLIXY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeltia sa-unspon adr (ZLIXY) Key Developments

Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Zeltia Reports Earnings Results for the Nine Months Ended September 2014

Zeltia reported earnings results for the nine months ended September 2014. For the period, the company's net sales grew by 7% year on year to EUR 116.9 million. Net profit amounted to EUR 17.5 million, a 24.3% increase compared with the same period in 2013. Positive performance was driven mainly by star oncology product Yondelis (trabectedin), net sales of which reached EUR 57 million, and the net sales of Biofarmacia increased by 7% to EUR 61.2 million.

Zeltia SA Presents at CF&B 14th Large & Midcap Event, Oct-02-2014

Zeltia SA Presents at CF&B 14th Large & Midcap Event, Oct-02-2014 . Venue: Palais Brongni, 28 Place de la Bourse, entrée Rue Vivienne, 75002 Paris, France.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZLIXY:US $0.00 USD 0.00

ZLIXY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZLIXY.
View Industry Companies
 

Industry Analysis

ZLIXY

Industry Average

Valuation ZLIXY Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 40.4x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA-UNSPON ADR, please visit www.zeltia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.